Corbus Pharmaceuticals: Experts React Positively to the Presented Clinical Phase 1/2 Study Data on CRB-701!

Reading Time: 5 minutes
Corbus Pharmaceuticals (CRBP) is currently standing out positively after reporting on ongoing studies. In October, an update on the clinical Phase 1/2 study of CRB-701 (SYS6002) was published at the European Society for Medical Oncology (ESMO) Congress 2025. The clinical biotechnology company focuses on the development of novel therapies in oncology and obesity, aiming to achieve a reassessment in the market through positive data from its pipeline. CRB-701 in Focus The reporting from Corbus Pharmaceuticals in October 2025 was clearly dominated...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.